For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Restructuring and other costs | - | - | - | 0 |
| Research and development | 1,459 | 1,441* | 249 | 667 |
| General and administrative | 2,169 | -1,246* | 1,975 | 2,452 |
| Impairment loss on other intangible assets | 3,700 | 1,295* | - | - |
| Impairment loss on goodwill | 8,430 | - | - | - |
| Merger-related costs | - | - | - | 0 |
| Impairment loss on other intangible assets | - | - | 5,180 | - |
| Total operating expenses | 15,758 | 1,490 | - | - |
| Loss from operations | -15,758 | -1,490* | -7,404 | -3,119 |
| Other expense, net | - | - | - | 0 |
| Interest income | - | 0* | 1 | 0 |
| Interest expense | 61 | 660* | 121 | 50 |
| Gain on settlement of current liabilities | 167 | 38* | 774 | 1,190 |
| Loss on debt extinguishment | - | -263* | -967 | - |
| Change in fair value of warrant liabilities | 44 | 195* | 253 | 134 |
| Gain on derivative liability | - | 70* | -100 | - |
| Change in fair value of derivative liability | 230 | - | - | - |
| Foreign currency exchange gain (loss), net | 64 | -482* | 76 | -50 |
| Total other income (expense), net | 444 | -1,103* | -84 | 1,224 |
| Net gain before income taxes | -15,314 | -2,594* | -7,488 | - |
| Benefit from deferred income taxes | -859 | 2,261* | -1,088 | - |
| Net loss | -14,455 | -4,855* | -6,400 | -1,895 |
| Foreign currency translation adjustment | 14 | 513 | -38 | -333 |
| Total other comprehensive income (gain), net of tax | 14 | 513* | -38 | -333 |
| Total comprehensive loss | -14,441 | -4,343 | -6,438 | -2,228 |
| Basic EPS | 0 | -0 | 0 | 0 |
| Diluted EPS | 0 | -0 | 0 | 0 |
| Basic Average Shares | 118,757,013,401 | 73,714,253,551 | 65,326,236,698 | 62,943,895,665 |
| Diluted Average Shares | 118,757,013,401 | 73,714,253,551 | 65,326,236,698 | 62,943,895,665 |
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)